VYNE Therapeutics Inc VYNE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.81
- Day Range
- $0.78–0.90
- 52-Week Range
- $0.28–1.60
- Bid/Ask
- $0.86 / $0.89
- Shares Outstanding
- 33.39M
- Market Cap
- $29.66M
- Volume/Avg
- 5M / 590,881
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 71.72
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 10
- Website
- https://www.vynetherapeutics.com
Valuation
|
Metric
|
VYNE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.09 |
Price/Sales | 76.14 |
Price/Cash Flow | — |
Price/Earnings
VYNE
Financial Strength
|
Metric
|
VYNE
|
|---|---|
Quick Ratio | 20.17 |
Current Ratio | 20.86 |
Interest Coverage | — |
Quick Ratio
VYNE
Profitability
|
Metric
|
VYNE
|
|---|---|
Return on Assets (Normalized) | −52.05% |
Return on Equity (Normalized) | −60.07% |
Return on Invested Capital (Normalized) | −60.04% |
Return on Assets
VYNE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|f#P@hB | LOCK|?j%! | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&>%kFx | LOCK|JFs? | $70B | |||
| argenx SE ADR
ARGX
| LOCK|^&dL!l^ | LOCK|K!> | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%m&WFqK | LOCK|zY | $37B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|HjJdr$ | LOCK|$^Z?> | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|H@yp@<@B | LOCK|z>#N | $25B | |||
| Moderna Inc
MRNA
| LOCK|q<Dnycg | LOCK|LM | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|n#!^&N | LOCK|?Wd | $23B | |||
| Incyte Corp
INCY
| LOCK|ny^&%! | LOCK|mgX | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|!t&^@#T | LOCK|vB | $16B |
United States